Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05626751 |
| Consolidated Lead Sponsor | Amgen |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 174 participants (ACTUAL) |
| Registered Start Date | 2022-11-04 |
| WhyStopped Classification | Safety / Toxicity / Adverse Events |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | Open Hospital Dossier -> |
| University of Michigan Rogel Cancer Center | Ann Arbor, MI | Open Hospital Dossier -> |
| Mayo Clinic Rochester | Rochester, MN | Open Hospital Dossier -> |
| Duke University Medical Center | Durham, NC | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.